N-Ethylpentylone (β-keto-ethylbenzodioxolylpentanamine, βk-ethyl-K, βk-EBDP, ephylone) is a
substituted cathinone and
stimulant drug which was developed in the 1960s.[2][3]
It has been reported as a novel
designer drug in several countries including the United Kingdom,[4] South Africa,[5] New Zealand,[6] the United States,[7] and Australia.[8]
In 2018, N-ethylpentylone was the most common drug of the cathinone class to be identified in
Drug Enforcement Administration seizures.[9]
In vivo studies in mice demonstrated that acute intraperitoneal administration of N-ethylpentylone induced an increase in locomotor activity, anxiolytic effects but also an aggressive behaviour as well as social exploration deficits. Repeated exposure to N-ethylpentylone induced hyperthermia, anorexia and rewarding effects. During withdrawal after repeated administration, depression-like symptoms, hyperlocomotion, and a decrease of social exploration were observed.[16][17]
^GB 1085135, "Substituted phenyl-α-amino ketones", published 1969, assigned to Boehringer Sohn Ingelheim
^Wood MR, Bernal I, Lalancette RA (October 2017). "The hydrochloride hydrates of pentylone and dibutylone and the hydrochloride salt of ephylone: the structures of three novel designer cathinones". Structural Chemistry. 28 (5): 1369–1376.
doi:
10.1007/s11224-017-0951-x.
ISSN1040-0400.
S2CID102424824.
^Blanco G, Vidler D, Roper C, Wood DM, Dargan PI, Keating L, et al. (December 2021). "Acute toxicity from the synthetic cathinone N-ethylpentylone (ephylone) in the United Kingdom". Clinical Toxicology. 59 (12): 1270–1273.
doi:
10.1080/15563650.2021.1909730.
PMID33855924.
S2CID233242607.
^Espinosa-Velasco M, Reguilón MD, Bellot M, Nadal-Gratacós N, Berzosa X, Puigseslloses P, et al. (January 2022). "Behavioural and neurochemical effects after repeated administration of N-ethylpentylone (ephylone) in mice". Journal of Neurochemistry. 160 (2): 218–233.
doi:
10.1111/jnc.15542.
hdl:2445/183029.
PMID34816436.
S2CID244528106.
N-Ethylpentylone (β-keto-ethylbenzodioxolylpentanamine, βk-ethyl-K, βk-EBDP, ephylone) is a
substituted cathinone and
stimulant drug which was developed in the 1960s.[2][3]
It has been reported as a novel
designer drug in several countries including the United Kingdom,[4] South Africa,[5] New Zealand,[6] the United States,[7] and Australia.[8]
In 2018, N-ethylpentylone was the most common drug of the cathinone class to be identified in
Drug Enforcement Administration seizures.[9]
In vivo studies in mice demonstrated that acute intraperitoneal administration of N-ethylpentylone induced an increase in locomotor activity, anxiolytic effects but also an aggressive behaviour as well as social exploration deficits. Repeated exposure to N-ethylpentylone induced hyperthermia, anorexia and rewarding effects. During withdrawal after repeated administration, depression-like symptoms, hyperlocomotion, and a decrease of social exploration were observed.[16][17]
^GB 1085135, "Substituted phenyl-α-amino ketones", published 1969, assigned to Boehringer Sohn Ingelheim
^Wood MR, Bernal I, Lalancette RA (October 2017). "The hydrochloride hydrates of pentylone and dibutylone and the hydrochloride salt of ephylone: the structures of three novel designer cathinones". Structural Chemistry. 28 (5): 1369–1376.
doi:
10.1007/s11224-017-0951-x.
ISSN1040-0400.
S2CID102424824.
^Blanco G, Vidler D, Roper C, Wood DM, Dargan PI, Keating L, et al. (December 2021). "Acute toxicity from the synthetic cathinone N-ethylpentylone (ephylone) in the United Kingdom". Clinical Toxicology. 59 (12): 1270–1273.
doi:
10.1080/15563650.2021.1909730.
PMID33855924.
S2CID233242607.
^Espinosa-Velasco M, Reguilón MD, Bellot M, Nadal-Gratacós N, Berzosa X, Puigseslloses P, et al. (January 2022). "Behavioural and neurochemical effects after repeated administration of N-ethylpentylone (ephylone) in mice". Journal of Neurochemistry. 160 (2): 218–233.
doi:
10.1111/jnc.15542.
hdl:2445/183029.
PMID34816436.
S2CID244528106.